Merus Labs International, Inc. (NASDAQ: MSLI) is on a quest to become a leading specialty pharmaceutical company with a diverse line of products in key global markets, with special geographic focus on North America and Europe. The Merus strategy is driven by an opportunistic, but highly disciplined approach to source product acquisition candidates. This approach allows Merus to source established pharmaceutical products across broad therapeutic categories. The company targets underdeveloped assets and optimizes their return through cost efficiencies, price opportunities and promotional efforts which drive volume growth. For more information, visit the company’s website at www.meruslabs.com.